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ABSTRACT
Background: The enzyme CYP1A2 (cytochrome 1A2) is involved
in the metabolism of certain drugs and caffeine, and its activity can
be influenced by factors such as sex, age, and smoking. The single
nucleotide polymorphism (SNP) rs762551A.C, which has also
been studied for its modifying effect on cardiovascular disease,
has been reported to alter enzyme activity.
Objective: The objective was to study the effect of CYP1A2, sex,
age, and smoking on coffee intake.
Design: Within the Rotterdam Study, a population-based cohort, all
coffee drinkers for whom genome-wide association data were avail-
able were selected. Because SNP rs762551 was not on the Illumina
550 platform, SNP rs2472299 was used as a proxy, with the A allele
of rs762551 linked to the G allele of rs2472299. Linear regression
analyses were used to determine the effect and interaction of
rs2472299, sex, age, and smoking on coffee intake. Adjusted geo-
metric means of coffee intake were calculated per genotype for the
different smoking and sex strata by using multivariable general
linear models. A combined analysis, with the use of a “risk score,”
was performed to determine the contribution of each separate factor.
Results: rs2472299G.A, female sex, and nonsmoking were signif-
icantly inversely related to coffee intake. Coffee intake was lowest in
nonsmoking women homozygous for rs2472299G.A (3.49 cups/d;
;436 mL). All factors contributed almost linearly to the intake of
coffee, with the highest coffee intake in smoking men without the A
allele (5.32 cups/d; ;665 mL).
Conclusion: rs2472299G.A, linked to rs762551A.C, sex, age,
and smoking significantly contribute to coffee intake. Am J
Clin Nutr 2012;96:182–7.
INTRODUCTION
Cytochrome 1A2 (CYP1A2)4 accounts for 13% of the total
hepatic content of cytochrome isoenzymes and plays a role in
the metabolism of various drugs, such as clozapine, olanzapine,
omeprazole, erythromycin, propranolol, and paracetamol (1, 2).
CYP1A2 is encoded by the CYP1A2 gene located on chromo-
some 15q24.1. The single nucleotide polymorphism (SNP)
rs762551A.C has been reported to alter enzyme activity. The
C allele, the variant allele in whites, is associated with a de-
crease in enzyme activity (2, 3). Polymorphisms within the
CYP1A2 gene were recently shown to be associated with coffee
intake (4–6). The pharmacologic effect of these variants re-
mains to be proven with experimental studies.
The activity of CYP1A2 can be influenced by factors such as
sex, age, and smoking. Sex has an influence that mainly seems to
be caused by the effect of the sex steroids. Overall, women have
a lower enzyme activity than men (7). Fluctuations in estradiol
concentrations cause fluctuations in enzyme activity; higher
estradiol concentrations result in a lower metabolic rate (8). In-
creasing agewas previously shown to be associated with a decrease
in enzyme activity, although not consistently (2, 9). Smoking is
responsible for induction of CYP1A2 enzyme activity (10, 11).
Caffeine is commonly used to measure the enzyme activity of
CYP1A2 by urinary caffeine metabolic ratios (3, 12, 13). Caf-
feine is almost completely metabolized via CYP1A2 to para-
xathine (82%), theobromine (11%), and theophylline (5%) (14).
Caffeine may have several negatively experienced effects on the
body, such as tachycardia, tremor, and flushing. These adverse
effects are influenced by CYP1A2 activity, sex, and smoking (15).
Coffee is one of the most widely consumed caffeine-containing
beverages. Certain diseases or health effects have been related to
coffee intake, such as a decrease in bone mineral density, a de-
creased risk of hormone-related cancer in women, and protection
against Parkinson disease and development of diabetes mellitus
(16–20). Regarding cardiovascular effects, coffee is associated with
an increased risk of hypertension (21), modified by rs762551A.C
(22). The effect on coronary artery disease is multifactorial and
inconclusive (23).
We conducted a study to investigate the effects of CYP1A2 on
coffee intake and the modifying effects of sex, age, and smok-
ing. We hypothesized that all of these factors, possibly by
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influencing enzyme activity, are related to coffee intake. The
aim of our study was to confirm the results from small experi-
mental studies with population-based data.
SUBJECTS AND METHODS
Cohort
This study was embedded in the Rotterdam Study (RS)—a
prospective population-based cohort study of neurologic, car-
diovascular, locomotor, and ophthalmologic diseases. All in-
habitants of Ommoord, a suburb of the city of Rotterdam in the
Netherlands, aged 55 y were invited in 1990 to participate in
the study. The medical ethics committee of the Erasmus Medical
Center approved the study, and informed consent was obtained
from all participants. The rationale and design of the study were
described elsewhere (24). The first cohort included 7983 in-
dividuals who were all interviewed and investigated at baseline
in the period 1990–1993. This cohort is designated RS-I. In
addition, in 2000 a second cohort (RS-II) was enrolled. All in-
habitants of Ommoord aged 55 y at that time and not yet
participating in RS-I were invited. This cohort encompasses
3011 individuals, who entered the study after consent. We in-
cluded all participants of RS-I and RS-II with successful gen-
otyping and positive coffee intake at baseline.
Outcome
Dietary intake data were collected at baseline between 1990 and
1993 for RS-I and between 2000 and 2001 for RS-II. Participants
were interviewed by a trained dietitian at the study center, who
used a validated semiquantitative food-frequency questionnaire
(25). In the interview, information on the amount and consumption
frequency of food items was collected. The participants reported
their habitual coffee and tea intake as number of cups per day or
week, which was recalculated into cups per day (1 cup of coffee is
assumed to contain 125 mL). Intake of non-caffeine-containing
coffee was defined as noncoffee intake. One cup of tea was
considered to contribute the caffeine content of 0.5 cups of coffee
(26, 27).
Genotyping
Microarray genotyping was performed in the whole original
RS cohort with proper quality DNA samples by using the
Infinium II HumanHap550K Genotyping BeadChip version 3
(Illumina). These methods were described in detail previously
(28). Because SNP rs762551 was not on the Illumina 550
platform, we extracted SNP rs2472299, which was in complete
linkage disequilibrium with rs762551, according to HapMap data
(release 22) (29). The A allele of rs762551A.C was linked to the
G allele of rs2472299G.A (30). In addition, SNPs rs2472297
and rs2470893 were extracted to include in the analysis as co-
variables. These SNPs are from previous genome-wide associ-
ation studies and were associated with coffee intake (4–6).
Covariables
Information on potential confounders and effect modifiers,
namely genotype, sex, age, and smoking, were gathered at baseline.
Smoking status was classified as current and noncurrent smoking,
because of its direct induction of the CYP1A2 enzyme (10).
Data analysis
The association of SNP rs2472299G.A, sex, age, and smoking
on coffee intake (in cups/d) was assessed cross-sectionally at
baseline by using linear regression models, including 95% CIs.
The major allele G was used as the reference to study the ge-
notype effect (GG, GA, or AA) of the SNP. In the analyses, we
adjusted for cohort (RS-I or RS-II) and the other covariables (sex,
age, and smoking). Effect modification was tested for genotype,
sex, age, and smoking by using interaction terms, adjusted and
unadjusted for the other covariables. To illustrate the differences
between the strata, adjusted geometric means were calculated per
genotype, sex, and smoking stratum by using multivariable gen-
eral linear models. To study the contribution of tea in the asso-
ciation with coffee (tea containing half of the amount of caffeine
compared with coffee), we performed an additional analysis in
which coffee and tea were combined as an outcome. To study the
contribution of the factors genotype, sex, and smoking on intake,
we created a risk model. Different variables were created of all
possible combinations of the contributing factors genotype, sex,
and smoking. The combination associated with the lowest coffee
intake was considered baseline risk. A P value ,0.05 was con-
sidered statistically significant. All statistical analyses were per-
formed with SPSS software (version 15.0; SPSS Inc).
RESULTS
Of the population of RS-I and RS-II, data on genotype were
available for 8126 participants. Within this group, coffee intake
was known for 6698 of the participants. After exclusion of par-
ticipants who do not drink coffee (n = 410), 6288 participants were
included in the study. Mean age was slightly lower in RS-II, and
RS-II contained more current smokers than did the first cohort.
Compared with the total cohort of the RS, the study population
was slightly younger and consisted of relatively more men and
more smokers (Table 1). No significant difference in genotype
pattern was found between the coffee drinkers and the partic-
ipants who did not drink coffee (data not shown).
Genetic effect
SNP rs2472299G.A had a minor allele (A) frequency of
27.0%. The distribution of the SNP did not deviate from
Hardy-Weinberg equilibrium. Intake of coffee was 20.19 cups/d
(95% CI: 20.29, 20.09; P , 0.0002) lower in carriers of one
minor allele (GA) than in carriers of 2 major alleles (GG).
Carriers of 2 minor alleles (AA) drank 20.34 cup/d less (95%
CI: 20.53, 20.15; P , 0.0005). In a univariate analysis, SNPs
rs2472297G.A and rs2470893G.A were significantly asso-
ciated with coffee intake in our population (P = 1.7 · 1028 and
P = 1.1 · 1027, respectively). In a multivariate analysis, after
adjustment for the individual effects of the SNPs, the SNP of
interest, rs2472299G.A, remained significantly associated with
coffee intake (P = 7.7 · 1026), but the effect of SNP
rs2472297G.A and rs2470893G.A was not significant (P =
0.14 and P = 0.10, respectively). The results for the total pop-
ulation and stratified for sex, age, and smoking are shown in
Table 2. Including the noncoffee drinkers in the analysis showed











similar results (GA: 20.20 cup/d, 95% CI: 20.30, 20.09; AA:
20.40 cup/d, 95% CI: 20.60, 20.40).
Sex, age, and smoking effect
Women drank less coffee than men, with a difference of 0.38
cup/d (95% CI: 20.48, 20.28). Age was associated with a sig-
nificantly decreased coffee intake in both men and women. Per
year of age, coffee intake declined by 0.07 cup/d (95% CI:20.07,
20.06). Coffee intake declined by 0.08 cup/d (95% CI: 20.09,
0.07) in men and by 0.06 cup/d (95% CI: 20.06, 0.05) in women
per year of age. Smoking was associated with a higher coffee
intake than was nonsmoking. Smokers drank almost 1 cup of
coffee (0.90 cup) per day more than did nonsmokers (95% CI:
0.79, 1.01).
Effect modification
Men showed a greater decline in coffee intake per variant allele;
statistical interaction between sex and genotype was significant
(P = 0.049; Table 2). This difference was more pronounced
within the nonsmoking stratum, but this higher-level interaction
could not be statistically confirmed (P = 0.05). No significant
interaction was found between genotype and age (P = 0.16) or
between genotype and smoking (P = 0.79).
The intake of coffee calculated per stratum is shown inFigure 1.
Smoking men without a variant allele drank ;50% more coffee
than did nonsmoking women with 2 variant alleles (5.32 6
0.11 cup/d compared with 3.49 6 0.11 cup/d). To illustrate the
effects after inclusion of tea to total caffeine intake, the analysis
was also performed for coffee and tea combined. The effects of
the separate determinants were less pronounced in this analysis,
indicating that the differences in effect between the strata were
less, although the effects show similar patterns (data not
shown). The genotype effect was significant for coffee and tea
combined (GA: 20.11 cup/d, 95% CI: 20.21, 20.01; AA:
20.41 cup/d, 95% CI: 20.60, 20.21), but not in all strata in the
stratified analysis. Effect modification by sex was not significant
(P = 0.70).
TABLE 1
Baseline characteristics of the participants1
Total cohort Study population
RS-I (n = 7983) RS-II (n = 3011) RS-I (n = 4473) RS-II (n = 1815)
Female sex [n (%)] 4878 (61) 1693 (56) 2608 (58) 966 (53)
Age (y) 70.6 6 9.82 65.2 6 8.4 67.5 6 7.6 64.6 6 7.9
Smoking [n (%)] 1725 (22) 942 (31) 1079 (24) 607 (33)
Genotype rs2472299G.A [n (%)]
GG 3202 (54) 1123 (52) 2383 (53) 950 (52)
GA 2359 (40) 862 (40) 1790 (40) 721 (40)
AA 409 (7) 171 (8) 300 (7) 144 (8)
Coffee intake (cups/d) 3.8 6 1.9 3.8 6 2.9 4.0 6 1.8 4.5 6 2.5
Tea intake (cups/d) 2.9 6 2.0 3.0 6 2.4 2.9 6 2.0 2.8 6 2.3
1 Differences in the characteristics sex, age, and smoking between the study population and the total cohort and
between RS-I and RS-II were significant (P , 0.05). Differences in coffee and tea intake were significant between all
groups, except for RS-I and RS-II in the total cohort for coffee and for RS-I (total cohort and study population) for tea. The
analyses were performed by using the chi-square test for binary variables and Student’s t test for continuous variables. G =
73%, A = 27%; Hardy-Weinberg equilibrium: v2 = 0.96. RS, Rotterdam Study.
2 Mean 6 SD (all such values).
TABLE 2
Effect of rs2472299G.A on coffee intake by genotype1
Change in coffee intake2
GG GA AA
n cups/d n cups/d n cups/d P-interaction
Total 3315 1.00 2505 20.19 (20.29, 20.09)3 441 20.34 (20.52, 20.16)3
Men 1449 1.00 1079 20.30 (20.46, 20.13)3 176 20.50 (20.82, 20.17)3 0.049
Women 1866 1.00 1426 20.10 (20.23, 20.02)3 265 20.24 (20.47, 20.02)3
Nonsmoking 2426 1.00 1836 20.18 (20.28, 20.08)3 312 20.33 (20.53, 20.13)3 0.79
Smoking 889 1.00 669 20.21 (20.45, 0.03) 129 20.37 (20.81, 0.08)
Age 65 y4 1640 1.00 1232 20.20 (20.37, 20.04)3 233 20.44 (20.74, 20.14)3 0.16
Age .65 y4 1675 1.00 1273 20.15 (20.26, 20.03)3 208 20.25 (20.47, 20.02)3
1 rs2472299G.Awas used as a proxy for the rs762551A.C genotype; smoking data are missing for 27 participants.
The analyses were performed by using the linear regression analysis.
2 95% CI in parentheses. Adjusted for sex, age, smoking, and cohort.
3 Statistically significant.
4 Age categories based on median; lower half and upper half.











Of the studied factors, age was responsible for 54% of var-
iation, followed by smoking (28%), sex (11%), and genotype
(8%). The effects of every additional determinant on coffee
intake, adjusted for age because of its continuous value, are
shown in Figure 2. Carriage of 2 variant alleles—female sex and
nonsmoking—were considered “baseline risk.” Carriage of one
or no variant alleles, male sex, and smoking were considered as
contributing to coffee intake. A linear effect could be distin-
guished in contribution of determinants.
DISCUSSION
Our study showed the contributing effects of genetic variance in
the CYP1A2 gene, sex, age, and smoking on coffee intake. Intake
was lowest in nonsmoking women with 2 variant alleles of
rs2472299G.A (AA genotype) and increased with the addition
of each of these factors. Smoking and sex were responsible for the
largest difference in coffee intake, followed by genetic effect.
Activity of CYP1A2, which is involved in the metabolism of
caffeine, explains only part of these results, because the effect of
sex, age, and smoking was independent of genotype and had a larger
effect on the intake than this genotype.
Influence of rs762551C.A on caffeine metabolism was
shown previously in experimental studies (2). In a small study
(n = 146) in a Turkish population, the metabolite ratio of caf-
feine after coffee intake was significantly influenced by carriage
of the A allele in smokers (explaining 19% of the variation in the
paraxanthine/caffeine metabolite ratio). The effect of age was
seen only in nonsmoking women. Smoking and sex explained
most of the variation (24% and 10%, respectively), whereas
rs762551C.A genotype and age explained ,1%. Our study
showed similar results regarding the contribution of sex, smoking,
and genotype. This is also in agreement with a previous ex-
perimental study on the toxicity of caffeine. Women and non-
smokers had the highest risk of toxic symptoms within a group
of 120 healthy volunteers (15).
The relation between rs762551A.C genotype and caffeine
intake was previously studied in a case-control study (31). No
significant association was found between coffee intake and
FIGURE 1. rs2472299G.A and coffee intake, per sex and smoking status. Values represent mean (6SE) coffee intake, adjusted for age and cohort;
rs2472299G.Awas used as a proxy for rs762551A.C, and smoking data are missing for 27 participants. Adjusted geometric means were calculated by using
multivariable general linear models.
FIGURE 2. Risk scores for rs2472299G.A, sex, and smoking in relation to coffee intake. Values are presented as b (6SE), adjusted for age and cohort;
rs2472299 is used as proxy for rs762551A.C. b Values were calculated by using linear regression analyses.











carriage of variant alleles. Three recent genome-wide associa-
tion studies on coffee consumption identified a relation between
SNPs within the gene-coding area of CYP1A1 and CYP1A2 and
coffee intake. Two SNPs were significantly associated with
coffee intake (rs2472297 and rs2470893) (4–6). These SNPs
were not linked to rs762551C.A; nonetheless, this suggests
a role of this gene-coding area in coffee intake. The relation
between rs762551C.A and coffee intake was present but was
not genome-wide significant (6). Our additional analysis showed
that the effect of rs2472297 and rs2470893 was not independent
of rs762551C.A. We showed the additional role of sex, age,
and smoking within our population. A significant effect of SNP
rs2472299G.Awas present in all strata in both men and women
and in both smokers and nonsmokers. Significant effect modifi-
cation was present between rs2472299G.A and sex (P , 0.05).
Differences in CYP1A2 activity have been attributed to the
effects of steroids (8, 32). Our study included only postmenopausal
women, which resulted in less of a difference in steroid pattern.
Therefore, it is hard to explain the role of these influences, which
might be overruled by other factors. In nonsmokers, genetic effects
seemed larger in men than in women, although the interaction
between sex and genotype within the nonsmoking stratum was not
significant (P = 0.05). Previous findings suggest of the influence
of genetic variation on caffeine metabolism is larger in smokers
(3). Smoking induces CYP1A2 by polycyclic aromatic hydro-
carbons in cigarette smoke (11).
One of the strengths of our study was the size of the population
with data on genotype and coffee intake. A potential limitation
was that the population was selected from the RS. Participants for
whom no blood could be drawn were excluded, as were those for
whom genotyping was unsuccessful. However, it is highly
probable that nonparticipation was independent of genotype, as
we showed in comparing our study population with the total
population. Selection bias was less likely, because genotype
distribution did not differ between coffee drinkers and partici-
pants without coffee intake. Random misclassification of the
outcome might have occurred because of the subjectivity of the
intake questions in the questionnaire. The additional value of
caffeine from decaffeinated coffee and tea could have led, most
probably nondifferentially, to misclassification because of the
definition we used. Furthermore, the participants’ habits may
have been temporary. These issues are most probably non-
differential. Caffeinated sodas were not included in the analyses;
however, given the age of the population, we did not expect
regular consumption. Data on genotype and coffee and tea intake
were prospectively recorded without knowledge of the research
question. Therefore, information bias is excluded. Drug use of
CYP1A2 inducers, such as omeprazole and carbamazepine, was
not taken into account. The effect of these drugs is most probably
nondifferential, because the use of these drugs might have
resulted in either an increase or a decrease in coffee intake be-
cause of the indication and effect of these drugs. In conclusion,
CYP1A2 genotype, sex, age, and smoking affect coffee intake.
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